Trial Profile

A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REC 4881 (Primary)
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms LILAC
Sponsors Recursion Pharmaceuticals

Most Recent Events

28 Nov 2024 Status changed from recruiting to active, no longer recruiting.
27 Feb 2024 According to a Recursion Pharmaceuticals media release, this study was initiated at the end of 2023, with FPI anticipated in Q1 2024. Also, the company expect to share Phase 2 safety and preliminary efficacy data in H1 2025.
02 Feb 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com